NASDAQ: MGRXMangoceuticals Inc Stock
$0.29-0.01 (-3.33%)
Updated Apr 19, 2024
MGRX Price
$0.29
Fair Value Price
N/A
Market Cap
$6.94M
52 Week Low
$0.14
52 Week High
$3.18
P/E
-0.52x
P/B
8.96x
P/S
6.1x
PEG
N/A
Dividend Yield
N/A
Revenue
$731.49k
Earnings
-$9.21M
Gross Margin
59%
Operating Margin
-1,259.4%
Profit Margin
-1,259.4%
Debt to Equity
0.36
Operating Cash Flow
-$7M
Beta
-0.07
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MGRX Overview
Mangoceuticals, Inc. focuses on develops, markets, and sells various men's wellness products and services through a telemedicine platform. It offers erectile dysfunction products under the Mango brand name. The company sells its products through online website mangorx.com. Mangoceuticals, Inc. was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. operates as a subsidiary of Cohen Enterprises, Inc.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MGRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MGRX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MGRX is poor value based on its book value relative to its share price (8.96x), compared to the US Health Information Services industry average (3.35x)
P/B vs Industry Valuation
MGRX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more MGRX due diligence checks available for Premium users.
Be the first to know about important MGRX news, forecast changes, insider trades & much more!
MGRX News
Valuation
MGRX fair value
Fair Value of MGRX stock based on Discounted Cash Flow (DCF)
Price
$0.29
Fair Value
$0.04
Overvalued by
722.73%
MGRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MGRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.52x
Industry
74.39x
Market
40.51x
MGRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
8.96x
Industry
3.35x
MGRX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MGRX's financial health
Profit margin
Revenue
$244.4k
Net Income
-$2.6M
Profit Margin
-1,050.9%
MGRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
MGRX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.1M
Liabilities
$276.0k
Debt to equity
0.36
MGRX's short-term assets ($818.46k) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MGRX's short-term assets ($818.46k) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MGRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.7M
Investing
$0.0
Financing
$1.2M
MGRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MGRX vs Health Information Service Stocks
Mangoceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.